

An international, multi-disciplinary, evidence-based consensus on the management of Barrett's dysplasia and early esophageal adenocarcinoma (BADCAT)

Authors:

Cathy Bennett^{*^ 1}, Nimish Vakil^{*^ 2}, Jacques Bergman^{*^ 3}, Rebecca Harrison^{*^ 4}, Robert Odze^{* 5}, Michael Vieth^{* 6}, Scott Sanders^{* 7}, Laura Gay^{* 8}, Oliver Pech^{* 6}, Gaius Longcroft- Wheaton^{* 9}, Yvonne Romero^{* 10}, John Inadomi^{*^ 11}, Jan Tack^{^* 12}, Douglas A. Corley^{*^ 13}, Hendrik Manner^{* 14}, Susi Green ^{*9}, David Al Dulaimi 15, Haythem Ali 16, Bill Allum 17, Mark Anderson 18,, Howard Curtis 19, Gary Falk 20, M. Brian Fennerty 21, Grant Fullarton 22, Kausilia Krishnadath 3, Stephen J. Meltzer 23, David Armstrong 24, Robert Ganz 25, Gianpaolo Cengia 26, James J. Going 22, John Goldblum 27, Charles Gordon 28, Heike Grabsch 29, 30, Chris Haigh 31, Michio Hongo 32, David Johnston 33, Ricky Forbes-Young 34, Elaine Kay 35, Philip Kaye 36, Toni Lerut 12, Laurence B. Lovat 37, Lars Lundell 38, Philip Mairs 39, Tadaoku Shimoda 40, Stuart Spechler 41, Stephen Sontag 42, Peter Malfertheiner 43, Iain Murray 44, Manoj Nanji 8, David Poller 9, Krish Ragunath 36, Jaroslaw Regula 45, Renzo Cestari 26, Neil Shepherd 46, Raj Singh 47, Hubert J. Stein 48, Nicholas J. Talley 49, Jean-Paul Galmiche 50, Tony C.K. Tham 51, Peter Watson 1, Lisa Yerian 28, Massimo Rugge 27, Thomas W Rice 27, John Hart 52, Stuart Gittens^{^ 53}, David Hewin^{^ 47}, Juergen Hochberger^{^ 54}, Peter Kahrilas^{^ 55}, Sean Preston^{^ 8}, Richard Sampliner^{^ 56}, Prateek Sharma^{^ 57}, Robert Stuart^{^ 58}, Kenneth Wang^{^ 10}, Irving Waxman^{^ 52}, Chris Abley 4, Duncan Loft^{” 59}, Ian Penman^{” 34}, Nicholas J. Shaheen^{” 60}, Amitabh Chak 61, Gareth Davies 62, Lorna Dunn 63, YngveFalck-Ytter^{^ 64}, John deCaestecker^{* 4}, Pradeep Bhandari^{* 10}, Christian Ell^{^* 9}, S Michael Griffin ^{*63}, Stephen Attwood^{*^ 65}, Hugh Barr^{*^ 46}, John Allen^{*^ 66}, Mark K. Ferguson^{*^ 52}, Paul Moayyedi^{*^ 25}, Janusz A Z Jankowski^{*^ 4,8,67}. (authors = 92)

1. Queens University, Belfast, UK
2. University of Wisconsin School of Medicine and Public Health, Madison WI, USA
3. Amsterdam Medical Center, The Netherlands
4. University Hospitals of Leicester, UK
5. Harvard Medical School, USA
6. Klinikum Bayreuth, Germany
7. Warwick medical School, UK
8. Queen Mary University London, UK
9. Portsmouth University Hospitals, UK
10. Mayo Clinic, USA
11. Washington University, Seattle, USA
12. Leuven University, Belgium
13. Kaiser Permanente, San Francisco, USA
14. Weisbaden Medical Centre, Germany
15. Redditch General Hospital, UK
16. Medway Hospital, Kent, UK
17. Royal Marsden Hospital, UK
18. City Hospital, Birmingham, UK and Sandwell Hospital, UK
19. Queen Marys Hospital, Sidcup, UK
20. University of Pennsylvania, USA
21. Oregon Health & Science University, Portland, USA
22. Royal Infirmary, Glasgow, UK
23. The Johns Hopkins University School of Medicine USA
24. McMaster University, Canada
25. Bloomington Medical Centre, Minnesota, USA
26. University of Brescia, Italy
27. Cleveland Clinic, USA
28. The Royal Bournemouth Hospital, UK
29. University of Leeds, UK
30. Leeds University Hospitals, UK
31. Wansbeck General Hospital, Northumbria, UK
32. Osaka University, Japan
33. Ninewells Hospital, Dundee, UK
34. Royal Infirmary, Edinburgh, UK
35. Trinity College, Dublin, Ireland
36. Queens Medical Centre, Nottingham, UK
37. University College London, UK
38. University of Stockholm, Sweden
39. Darrent Valley Hospital, Kent, UK
40. Kyoto University, Japan
41. University of Dallas, USA
42. Loyola University, USA
43. Magdeburg University, Germany
44. Royal Cornwall Hospitals, UK
45. Institute of Oncology, Warsaw, Poland
46. Gloucestershire Royal Hospitals, UK
47. Royal Adelaide Hospital, Australia
48. Polyclinic Klinikum Munchen, Germany
49. University of Newcastle, Australia
50. Department of Gastroenterology, CHU and University, Nantes France

51. Ulster Hospital, Belfast, UK
52. University of Chicago, USA
53. ECD Solutions, USA
54. University Nurnberg-Erlangen, Germany
55. Northwestern University, USA
56. University of Tucson, Arizona, USA
57. University of Kansas, USA
58. Oesophageal Cancer Fund, Dublin, Ireland
59. Walsgrave Hospital, Coventry, UK
60. North Carolina Medical School, USA
61. Case Western Reserve Medical School, USA
62. Harrogate Hospital, UK
63. University of Newcastle, UK
64. Louis Stokes Medical Centre, USA
65. Durham University, UK
66. University of Minnesota School of Medicine, USA
67. University of Oxford, UK

Correspondence to:

1. Prof Janusz A Z Jankowski MSc, MB ChB, MD, PhD, FRCP, FACG, AGAF

Centre for Digestive Diseases

Blizard Institute

Queen Mary, University of London,

4 Newark St, Whitechapel, London

EC1 2AT

J.a.jankowski@qmul.ac.uk

And

2. Prof Paul Moayyedi BSc, MB ChB, PhD, MPH, FRCP (London), FRCPC, AGAF, FACG

Department of Medicine, McMaster University Medical Centre

1200 Main Street West, HSC 4W8E

Hamilton, ON, L8N 3Z5, Canada

moayyep@mcmaster.ca

Short title: Consensus statement for HGD in Barrett's

Funding:

International Society of Diseases of the Esophagus \$3500, British Society of Gastroenterology £2,500, American College of Gastroenterology \$2000, American Gastroenterological Association \$2000, American Society for Gastrointestinal Endoscopy \$2000, Association of Upper Gastrointestinal Surgeons £1000, Fight Oesophageal Reflux Together £1,000, German Society of Endoscopy €2000, Netherlands Association of Hepatogastroenterologists €1,100, Oesophageal Cancer Research Fund €3000

(ISDE and BSG had the largest financial commitment)

Abstract

Background: Esophageal adenocarcinoma (EA) is an increasingly common and often fatal condition, which occurs in a background of Barrett's esophagus (BE).

Aim: To provide consensus recommendations, based on current medical literature, to assist clinicians in making decisions about the management of low grade dysplasia, high-grade dysplasia (HGD) and early EA in BE patients.

Method: We created an international multi-disciplinary, systematic, evidence-based review on the management of BE with dysplasia or early EA. We used a Delphi process to develop consensus statements. The results of literature searches were screened using a unique interactive web based data sifting platform and we identified 11,904 papers to inform the choice of statements selected. An *a priori* threshold of 80% agreement was used to establish consensus for each statement.

Results: Eighty-one of the 91 statements achieved consensus despite generally low quality of evidence, including 8 statements with key clinical messages: 1. Endoscopic resection specimens provide better staging for lesions than do biopsies. 2. Careful mapping of the size of the dysplastic areas is important. 3. Endoscopic follow-up is still required post-ablation or after surgery. 4. The use of high-resolution endoscopes is necessary for accurate diagnosis. 5. Endoscopic therapy for HGD is preferred to surveillance. 6. Endoscopic therapy for HGD is preferred to surgery. 7. Endoscopic resection combined with radiofrequency ablation is the most effective therapy. 8. Endoscopic ablation of all BE in patients with HGD is recommended following endoscopic removal of lesions.

Conclusions: We used a novel data-sifting platform exploiting the Delphi process to achieve one of the largest ever evidence-based consensus documents in gastroenterology. We established key clinical messages and identified several areas for future study.